Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 550

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1C
Chunk 550
---
. Dr. Brown holds a Ph.D. in synthetic chemistry
from the University of Alabama, and an M.D. from the University of Virginia. He is an elected fellow of the National Academy of Inventors
(FNAI). His extensive experience and expertise in drug discovery makes him uniquely qualified to guide the Company’s drug discovery
program as a member of our Board of Directors.

71

Steven
Richards. Mr. Richards was appointed to be a member of our Board of Directors in 2019. He is Chief
Executive Officer and Founder of Endurance Media, a media finance company based in Santa Monica, California, that launched in
2014 with a strategic alliance with eOne Entertainment and a mandate to produce and finance commercially driven feature films. From 2006
to 2014, Mr. Richards served as Co-President and Chief Operating Officer of Silver Pictures where he oversaw all business activities
and managed a team of more than 20 people responsible for film development, production, and financial information. From 2000 to 2006,
he served as Chief Financial Officer at Silver Pictures and from 1995 to 2000 as Vice President, Finance, at Silver Pictures. Mr. Richards
holds an MBA in Finance from UCLA, a BBA in accounting from Temple University, and holds his CPA license. We believe his experience as
a chief financial officer and his knowledge of accounting will assist in providing guidance and oversight to our Board of Directors as
we grow our Company.

Joshua
Schafer. Mr. Schafer was appointed to be a member of our Board of Directors in 2019. From January 2023 until present, Mr. Schafer
has been serving as the Chief Commercial Officer, and EVP Business Development at Zevra Therapeutics, a rare disease company. From November
2022 until January 2023, Mr. Schafer was interim Chief Executive Officer and Chair of the
board of directors at PHARNEXT, an entity he has served on the board of directors since July 2020. From December 2020 until November
2022, Mr. Schafer served as Senior Vice President and General Manager, Autoimmune and Rare Disease Business for Mallinckrodt Pharmaceuticals
Incorporated. In addition, he served as Chief Strategy and Business Development Officer from September 2019 until December 2020, and
from 2015 to September 2019 he was SCP of Business Development and General Manager of International Operations at Mallinckro